Top Markets
Coin of the day
Wuhan Hiteck Biological Pharma Co.,Ltd Wuhan Hiteck Biological Pharma Co.,Ltd

Wuhan Hiteck Biological Pharma Co.,Ltd

300683
주식 순위 #13466
Wuhan Hiteck Biological Pharma Co.,Ltd is a biopharmaceutical enterprise... Wuhan Hiteck Biological Pharma Co.,Ltd is a biopharmaceutical enterprise operating in China, primarily engaged in the research, development, manufacturing, and commercialization of bio-engineered products and lyophilized injectable medications. The company's extensive product portfolio encompasses a variety of pharmaceutical solutions, such as Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye acyclovir tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository; Xunkeyuan tinidazole suppository; and Shufu nimodipine sustained-release tablets. Beyond therapeutics, Wuhan Hiteck also provides a comprehensive array of diagnostic kits. These include tests for measles virus and rubella virus nucleic acid, mycoplasma isolation and identification, bacterial vaginosis rapid detection, measles virus IgG antibodies, and the coronavirus N-protein. Furthermore, the firm supplies active pharmaceutical ingredients (APIs) and their chemical intermediates, notably Lopinavir and Ritonavir. Its core therapeutic areas of focus are the nervous system and oncology. Established in 1992, Wuhan Hiteck Biological Pharma Co.,Ltd is headquartered in Wuhan, China.
주가
$3.71
시가총액
$486.16M
변동 (1일)
-0.97%
변동 (1년)
-45.64%
국가
CN
거래 Wuhan Hiteck Biological Pharma Co.,Ltd (300683)

카테고리

Wuhan Hiteck Biological Pharma Co.,Ltd (300683)의 발행 주식 수
August 2026 기준 발행 주식 수: 0
Wuhan Hiteck Biological Pharma Co.,Ltd의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 0입니다. August 2026 말 기준 회사는 0주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Wuhan Hiteck Biological Pharma Co.,Ltd (300683)의 발행 주식 수 기록 (2026 ~ 2026)
매년 말 기준 발행 주식 수
연도 발행 주식 수 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 발행 주식 수